Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
His Cancer Journey Shows Health Dangers Firefighters Face
FRIDAY, May 10, 2024 -- For 14 years, David Perez fought fires in South Florida, thinking he was in peak physical shape. Then a routine physical turned up...
Baby Girl Born Deaf Gains Hearing After Gene Therapy
FRIDAY, May 10, 2024 -- Opal Sandy was born into a world she could not hear. The British baby girl, now 18 months old, had a rare genetic condition called...
Cyberattack Cripples Major U.S. Health Care Network
FRIDAY, May 10, 2024 -- Ascension, a major U.S. health care system with 140 hospitals in 19 states, announced late Thursday that a cyberattack has caused...
Cancer Patients Often Face Medical Debt, Even With Insurance
FRIDAY, May 10, 2024 -- When cancer strikes, you could easily go into debt, even with health insurance in place, according to a new survey from the American...
One in 8 U.S. Adults Have Now Used Blockbuster Meds Like Ozempic
FRIDAY, May 10, 2024 -- About 1 in 8 U.S. adults (12%) have tried a weight-loss drug like Wegovy, Ozempic, Zepbound or Mounjaro, a new KFF Health Tracking...
Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine
THURSDAY, May 9, 2024 -- Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study...
Those With Limited English Proficiency Face Barriers to Telehealth
THURSDAY, May 9, 2024 -- For individuals with limited English proficiency, there are disparities in telehealth access, as well as worse video visit...
Researchers Quantify the Risk for Diabetes After Gestational Diabetes
THURSDAY, May 9, 2024 -- Gestational diabetes is associated with an increased risk for subsequent diabetes, with higher risk for gestational diabetes in...
Racial, Ethnic Differences Seen in Breast Cancer Treatment Declination
THURSDAY, May 9, 2024 -- For patients with breast cancer, there are racial and ethnic differences in treatment declination, according to a study published...
Symptom Burden Prevalent in Childhood Cancer Survivors
THURSDAY, May 9, 2024 -- Symptom burden is prevalent among young childhood cancer survivors, with caregiver anxiety and greater neighborhood deprivation...
FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection
WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to...
US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo (adalimumab-adbm) injection
RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved...
FDA Approves Libervant (diazepam) Buccal Film for the Treatment of Seizure Clusters in Pediatric Patients Ages 2-5 Years
WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a...
FDA Approves Xolremdi (mavorixafor) for Use in Patients with WHIM Syndrome
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune...
Abeona Therapeutics Provides Regulatory Update on Pz-cel
CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced a regulatory update for prademagene zamikeracel (pz-cel)...
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., April 8, 2024 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
DUBLIN, April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a...
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
2 April 2024 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
Bayer to Unveil Late-Breaking Data from Phase III OASIS 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause
Berlin, May 8, 2024 – 08 May 2024 -- Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and...
Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown Effective
May 8, 2024 -- Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking...
Positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM, May 6, 2024. Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead...
NRx Pharmaceuticals Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
RADNOR, Pa., May 6, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical...
Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
SAN ANTONIO, May 3, 2024. Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.